Lv6
2130 积分 2021-09-04 加入
工作太多了！
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
23天前
已关闭
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
23天前
已完结
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
25天前
已完结
Advancements in immunotherapy for hepatocellular carcinoma
27天前
已完结
Immunotherapies for hepatocellular carcinoma
27天前
已完结
Combination locoregional and systemic therapies in hepatocellular carcinoma
27天前
已完结
Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials
27天前
已完结
Evolving therapeutic landscape of advanced hepatocellular carcinoma
1个月前
已完结
Neutrophil profiling illuminates anti-tumor antigen-presenting potency
1个月前
已完结
A blueprint for tumor-infiltrating B cells across human cancers
1个月前
已完结
皖公网安备34019202002308
